ID
45332
Description
Principal Investigator: Arul M. Chinnaiyan, MD, PhD, University of Michigan, MI, USA MeSH: Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000554 Exome sequencing of matched pairs of tumor / normal genomic DNA was performed from high risk localized prostate cancer or lethal, metastatic, castrate resistant prostate cancer (CRPC). Exome libraries were prepared using Illumina Paired_End Genome DNA Sample Prep Kit and captured using Agilent SureSelect Capture Library or Roche EZ Exome capture library. Sequencing was performed on Illumina GAII and HiSeq 2000 platforms in paired end mde, with 80 base pair reads from the final library fragments. Copy number alterations and somatic mutations were identified.
Link
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000554
Keywords
Versions (2)
- 10/31/22 10/31/22 - Simon Heim
- 12/13/22 12/13/22 - Kristina Keller
Copyright Holder
Arul M. Chinnaiyan, MD, PhD, University of Michigan, MI, USA
Uploaded on
October 31, 2022
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs000554 Mutational Landscape of Lethal Castrate Resistant Prostate Cancer
Subject ID, consent group, subject source, and subject source ID of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- StudyEvent: SEV1
- Subject ID, consent group, subject source, and subject source ID of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Subject ID, sample ID, sample source, sample source ID, and sample use variable of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Subject ID, age, ERG gene rearrangement in tumor, ETV1 gene rearrangement in tumor, SPINK1 gene outlier over-expression in tumor, SPINK1 gene outlier over-expression in tumor of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Sample ID and GEO accession of samples obtained from patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of samples, histological type of samples, tumor Gleason score of sample, serum PSA, type of tumor treatment, survival in months after diagnosis, survival in months after first hormone therapy, survival in months after first chemotherapy, alias name of samples obtained from patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
Similar models
Subject ID, consent group, subject source, and subject source ID of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- StudyEvent: SEV1
- Subject ID, consent group, subject source, and subject source ID of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Subject ID, sample ID, sample source, sample source ID, and sample use variable of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Subject ID, age, ERG gene rearrangement in tumor, ETV1 gene rearrangement in tumor, SPINK1 gene outlier over-expression in tumor, SPINK1 gene outlier over-expression in tumor of patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Sample ID and GEO accession of samples obtained from patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of samples, histological type of samples, tumor Gleason score of sample, serum PSA, type of tumor treatment, survival in months after diagnosis, survival in months after first hormone therapy, survival in months after first chemotherapy, alias name of samples obtained from patients with prostate cancer and involved in the "Mutational Landscape of Lethal Castrate Resistant Prostate Cancer" project.
C1257890 (UMLS CUI [1,2])
C3847505 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,2])
C3847505 (UMLS CUI [1,3])
No comments